Telo Genomics Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Allen Farlinger
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 555 Richmond Street West Toronto ON Canada M5G 1L7
- IPO Date
- Jan 8, 2021
- Website
- telodx.com
- Similar Companies
- Business
- Telo Genomics Corp. (TDSGF) develops and commercializes innovative genomic testing solutions focused on precision medicine, particularly in oncology. The company offers the TELOMERE-PRO™ test, a prognostic biomarker assay that measures telomere length in circulating tumor cells to predict disease progression and treatment response in metastatic cancers; the Start_Test, a telomere length screening service for early cancer risk assessment; and related genomic services including telomere analytics platforms and custom research assays. Headquartered in Toronto, Canada, and founded in 2014, Telo Genomics operates primarily in North America, targeting oncologists, healthcare providers, and pharmaceutical researchers in the biotechnology and diagnostics sectors. In recent developments, the company rebranded from Telo Inc. to Telo Genomics Corp. in 2024 to better reflect its focus on genomic technologies and expanded its commercial pipeline with the full launch of TELOMERE-PRO™ following FDA Breakthrough Device Designation in late 2023. Telo Genomics also formed strategic partnerships with leading cancer centers for clinical validation studies and secured non-dilutive funding through Canadian government grants in 2025 to support manufacturing scale-up and market expansion into the U.S. and Europe. These initiatives mark a shift toward broader adoption in precision oncology, with ongoing efforts to integrate AI-driven analytics into its telomere testing portfolio.
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
Telo Genomics Announces Termination of Investor Relations Agreement
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement
Telo Genomics Closes First Tranche of Convertible Debentures Financing
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program
Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th
Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025
American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting
Telo Geonomics Announces Engagement of Investor Relations Service Provider
Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference
Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference